Physician profile
Parisa Mehran
NPI 1699159939
$5,870.72
in general payments reported to CMS, 2019-2025
32 companies · $1,736 in 2025
The $1,736 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $43.36 · 2021: $49.36 · 2022: $1,172 · 2023: $836 · 2024: $2,033 · 2025: $1,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,591 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,591.04 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,130.06 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $849.47 | 2022-2025 | Evenity, Tepezza, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $766.92 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $709.19 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $695.64 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Radius Health, INC. | $344.99 | 2022-2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $167.05 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Alexion Pharmaceuticals, INC. | $132.27 | 2022-2024 | Strensiq |
| Corcept Therapeutics | $99.94 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $89.72 | 2021-2023 | Farxiga |
| Mannkind Corporation | $79.21 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $77.46 | 2022 | |
| Sanofi-Aventis U.S. LLC | $66.07 | 2023-2025 | |
| Dexcom, INC. | $65.18 | 2024-2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $59.19 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $58.06 | 2022 | |
| Astellas Pharma US INC | $54.38 | 2024 | Veozah |
| Inspire Medical Systems, INC. | $49.74 | 2023 | Inspire |
| Glaxosmithkline, LLC. | $43.01 | 2022 | |
| Verity Pharmaceuticals INC. | $42.86 | 2024-2025 | Tlando |
| Madrigal Pharmaceuticals | $31.27 | 2025 | Rezdiffra |
| Beta Bionics, INC. | $26.17 | 2024 | Ilet Bionic Pancreas |
| Soleno Therapeutics, INC. | $26.04 | 2025 | Vykat Xr |
| Recordati_rare_diseases_inc. | $25.99 | 2025 | Isturisa |
| Alvogen INC | $25.81 | 2023 | Teriparatide |
| Ascendis Pharma Endocrinology INC | $25.49 | 2025 | Yorvipath |
| Almatica Pharma LLC | $24.85 | 2025 | Teriparatide |
| Echosens North America, INC. | $24.08 | 2024 | Fibroscan |
| Horizon Therapeutics Plc | $22.10 | 2022 | |
| Tandem Diabetes Care, INC. | $21.62 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $21.43 | 2025 | Twiist |
| Medtronic, INC. | $15.46 | 2025 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parisa Mehran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.